Clinical trial
Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in…
NCT00439010 · Molecular NeuroImaging, Other · Completed
Key facts
| NCT number | NCT00439010 |
|---|---|
| Title | Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects |
| Official title | Evaluation of [123I] AV39 and SPECT as a Marker of Beta-Amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects |
| Lead sponsor | Molecular NeuroImaging, Other |
| Collaborators | Institute for Neurodegenerative Disorders |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Alzheimers Disease |
| Intervention type | Drug |
| Interventions | [123I] AV 39 |
| Enrollment | 30 |
| Start date | Feb 1, 2007 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Feb 22, 2007 |
| Last update posted | Apr 24, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: